Haemate P

Haemate P is a prescription intravenous solution containing human coagulation factor VIII and human von Willebrand factor. It is supplied as a sterile concentrate for intravenous infusion. The product is used in the European market to replace deficient clotting factors in patients with hemophilia A or von Willebrand disease. Its formulation provides both factor VIII and von Willebrand activity in a single preparation for treatment.

Haemate P is indicated for the management of bleeding disorders related to factor VIII deficiency.

- Treatment of acute bleeding episodes in patients with hemophilia A. - Routine prophylaxis to prevent spontaneous bleeds in hemophilia A. - Management of bleeding and surgical prophylaxis in von Willebrand disease of any type. - Replacement therapy during major surgery or invasive procedures in patients lacking factor VIII or von Willebrand factor. - Supportive therapy in patients with combined factor VIII and von Willebrand factor deficiency.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Headache, fever, chills, or infusion‑related reactions such as erythema at the site. - Nausea, vomiting, or abdominal discomfort. - Transient elevations in liver enzymes. - Mild allergic symptoms like rash or itching.

Serious: - Development of inhibitors (antibodies) against factor VIII, reducing efficacy. - Severe allergic reactions including anaphylaxis. - Thrombotic events such as deep vein thrombosis. - Renal impairment or hemolysis in rare cases.

Clinicians should consider several precautions when prescribing Haemate P to ensure safe use.

- Screen for pre‑existing factor VIII inhibitors before initiating therapy. - Monitor inhibitor titres regularly during long‑term treatment. - Use caution in patients with a history of allergic reactions to plasma‑derived products. - Adjust dose in individuals with renal or hepatic impairment. - Avoid rapid infusion rates to reduce risk of infusion‑related reactions. - Observe for signs of thrombosis, especially in patients receiving concurrent pro‑coagulant agents.

Haemate P may interact with other medications that affect coagulation or immune response.

Avoid: - Concomitant use of other factor concentrates without medical supervision. - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs that increase bleeding risk.

Use with caution: - Immunosuppressive agents that may alter inhibitor development. - Antifibrinolytic agents (e.g., tranexamic acid) when used together, requiring dose adjustment. - Other intravenous products administered through the same line without proper flushing.